Bioventus Selects Bazis NN as Distributor of DUROLANE® in Russia
15.6.2020 16:00:00 EEST | Business Wire | Press release
Bioventus, a global leader in orthobiologic solutions, has selected Bazis NN as its authorized distributor for DUROLANE, its single-injection joint-fluid osteoarthritis (OA) treatment. OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200615005023/en/
DUROLANE is a single-injection, hyaluronic acid product used for joint lubrication in the treatment of pain associated with osteoarthritis in the knee, hip and small joints. (Photo: Business Wire)
According to official statistics, patients with OA make up one quarter of all patients with musculoskeletal system diseases and OA is detected in 4% of the entire adult population.1 Hyaluronic acid (HA)-based products like DUROLANE and DUROLANE SJ help manage pain in the knees, hips, wrists, elbows, ankles, finger and toe joints of patients with OA.
“We believe the OA market in Russia is underserved and the patients there will benefit greatly from DUROLANE,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Bazis has a terrific track record in marketing and selling orthopaedic solutions in Russia and we are pleased they are helping Bioventus reach more patients and physicians with our proven pain reliever for osteoarthritis.”
“Bazis has been serving patients and physicians in Russia for more than 16 years,” said Aleksandr Alekseev, Director, Bazis NN. “We are excited to offer DUROLANE for knee and hip and DUROLANE SJ for small joints. Both are safe, single injection options for patients that provide powerful and long-lasting OA pain relief.”
DUROLANE and DUROLANE SJ are produced using a natural, safe and proven process called NASHA ® . This process yields stabilized (HA) which is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. It has been proven to provide greater reduction in OA knee pain versus Synvisc-One®2* and longer lasting pain relief versus a steroid injection3. DUROLANE is also safe for repeated courses of therapy. Repeated use of DUROLANE does not increase the incidence of adverse events.4
About Bioventus
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, www.bioventusglobal.com and follow the company on LinkedIn and Twitter.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
Summary of Indication for Use: DUROLANE (3ml): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. DUROLANE SJ (1ml): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes. DUROLANE SJ is also indicated for pain following joint arthroscopy in the presence of osteoarthritis within three months of the procedure. There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant and breastfeeding women, and in children. Risks can include transient pain, swelling and/or stiffness at the injection site. Indications presented are those approved in Russia; indications and product offerings vary by country. Consult with your local Bioventus representative for approved use within your region of interest. Full prescribing information can be found in product labeling, at www.durolane.com.(1mL / 3mL).
References: 1. Kabalyk M.A. Prevalence of Osteoarthritis in Russia: Regional Aspects of Trends in Statistical Parameters During 2011–2016 Rheumatology Science and Practice. 2018;56(4):416-422. (In Russ.) doi:10.14412/1995-4484-2018-416-422. 2. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2018.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005023/en/
Contact information
Thomas Hill
919-474-6715
thomas.hill@bioventusglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kioxia to Expand 3D Flash Memory Production Capacity with the New Fab3 at Kitakami Plant27.8.2026 14:20:00 EEST | Press release
Kioxia Corporation, a world leader in memory solutions, announced today that it has commenced site preparation and other related work for the construction of Fab3, a new state-of-the-art manufacturing facility at the Kitakami Plant in Iwate Prefecture, Japan, to expand production capacity for advanced three-dimensional flash memory BiCS FLASH™. Fab3 will be constructed on land south of Fab2, targeting operations to commence in fiscal 2029. The flash memory market is expected to continue to expand significantly in the medium to long term, driven by agentic AI, physical AI, and on-device AI. Through the construction of Fab3, Kioxia aims to meet rising market demand by expanding production and ensuring stable supply of cutting-edge flash memory products. Detailed plans for Fab3 regarding construction schedule and equipment investments will be determined based on market trends. Investment plans for Fab3 are contingent upon government support. Under its mission to “uplift the world with ‘me
Quaise Energy Closes $180 Million Series B with $35 Million Investment from Nabors Industries and Strategic Framework to Build World's First Superhot Geothermal Power Plant27.8.2026 14:05:00 EEST | Press release
Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced the final close of its Series B, raising a total of $180 million in equity financing, including a $35 million investment from Nabors Industries (NYSE: NBR), one of the world's largest land drilling contractors and a long-standing partner to Quaise. Nabors has also entered into a strategic framework agreement that supports Quaise’s mission to make superhot geothermal a commercial reality, beginning with the development of Project Obsidian, the world’s first superhot geothermal power plant. The Series B brings Quaise’s total funding to date to $280 million. “We are unlocking the most powerful clean energy source on Earth, and the Series B signals deep conviction across a wide range of investors,” said Carlos Araque, CEO and President, Quaise Energy. “Nabors is an invaluable partner as we move millimeter wave drilling to full commercial operations at Project Obsidian and beyond.” Nabors’ invest
83% of Chinese Consumers Use Quick Commerce, Offering a Glimpse into Grocery's Future27.8.2026 13:30:00 EEST | Press release
The next major shift in retail may not be happening on shelves. It is happening in the everyday grocery basket, where speed, convenience and top-up missions are reshaping how consumers buy. Quick commerce is emerging as a core engine of grocery growth, according to NIQ (NYSE: NIQ), a leading consumer intelligence company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824560517/en/ Asia is leading the quick commerce revolution, with adoption rates of 83% in China and 82% in India. NIQ's global report, The Commerce Revolution: Where East Meets West, finds that ultra-fast delivery is already mainstream across parts of Asia, offering a preview of how commerce is likely to evolve globally. The clearest signs of this shift can be seen in China and India, where quick commerce adoption has reached 83% and 82%, respectively, far exceeding the global average of 48%. By comparison, adoption stands at 34% in Europe and just 3% in No
74% of Shoppers Use AI for Discovery—NIQ Showcases What That Means for the Consumer Purchase Journey in New Report27.8.2026 13:00:00 EEST | Press release
Consumers are increasingly turning to new technologies to help navigate a more complex shopping landscape. Nearly three-quarters of shoppers now use AI for product discovery, while retail media has grown into a $184 billion global market. Together, these shifts are reshaping how products are discovered, evaluated, and ultimately purchased. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827177247/en/ AI is becoming the new gatekeeper of product discovery. NIQ has released A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, a new global report in collaboration with World Data Lab showing how artificial intelligence, retail media networks, and social commerce are transforming the path to purchase and influencing which products consumers ultimately buy. The findings build on NIQ's recently released The Commerce Revolution: Where East Meets West, which identified the convergence of Eastern commerce in
Ant International Joins Hong Kong Regulators’ GenA.I. Sandbox++ to Advance Bank Liquidity Management with AI27.8.2026 13:00:00 EEST | Press release
Ant International’s Ant Bank, a digital bank based in Hong Kong, and Bettr, its inclusive embedded financial solutions provider, have been selected to participate in Hong Kong regulators’ GenA.I. Sandbox++, focusing on the liquidity risk management track. Ant Bank will leverage Ant International's Falcon Time-Series Transformer (TST) AI Model 2.0 to enhance its FX and liquidity management capabilities. The partnership will deploy granular, statistically-grounded daily forecasts, to support more precise and proactive liquidity planning for the bank's real-time treasury management — strengthening its capabilities to support a 24/7 financial ecosystem. As Hong Kong's only digital bank deeply integrated with an e-wallet, Ant Bank aims to leverage technology to provide innovative, inclusive and customer-centric digital financial services. To enhance customer experience, the bank sought to integrate AI and LLM technology to improve the accuracy of its cashflow predictions — reflecting its cu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom